Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

This publication has 38 references indexed in Scilit:

• Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis
  Arthritis Research & Therapy, 2014
• Cytokine-Mediated Regulation of Plasma Cell Generation: IL-21 Takes Center Stage
  Frontiers in Immunology, 2014
• Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis
  Annals of the Rheumatic Diseases, 2012
• Sustained Remission of Multicentric Castleman Disease in Children Treated with Tocilizumab, an Anti-Interleukin-6 Receptor Antibody
  Molecular Cancer Therapeutics, 2012
• Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells
  Annals of the Rheumatic Diseases, 2011
• In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment
  Arthritis & Rheumatism, 2011
• Circulating Antibody‐Secreting Cells during Acute Respiratory Syncytial Virus Infection in Adults
  The Journal of Infectious Diseases, 2010
• IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production
  Blood, 2010
• Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation study
  Arthritis & Rheumatism, 2010
• Interleukin 6 is not required for antigen‐specific antibody responses by human B cells
  European Journal of Immunology, 1993